2026.07.17

ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor

ThalassaX Therapeutics Announces First Patient Dosed in U.S. Phase I Trial of CS231295, a Brain-Penetrant Aurora B Kinase Selective Inhibitor

Full text

2026.07.15

Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma

Chipscreen Biosciences' Partner HUYABIO Announces Positive Topline Data from Global Multicenter Phase III Trial of Chidamide (Epidaza®) in Melanoma

Full text

2026.06.12

Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem

Chipscreen Biosciences Attends the 2026 SAPA Healthcare Investment Forum, Engaging with the Global Innovation Ecosystem

Full text

2026.05.25

From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released

From Glycemic Control to Addressing Metabolic Root Causes: “White Paper on the Current Status and Future of Comprehensive Insulin Resistance Management in China (2025)” Officially Released

Full text

2026.05.14

Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access

Two First-in-Class Drugs from Chipscreen Biosciences Enter the Macao Market, Expanding Patient Access

Full text

2026.04.23

2026 ASCO丨Multiple innovative Drug Studies from Chipscreen Biosciences Selected

2026 ASCO丨Multiple innovative Drug Studies from Chipscreen Biosciences Selected

Full text

2026.04.23

Published in JAMA ! Chidamide DEB Study Reshapes the First-Line Treatment Landscape for DE-DLBCL

Published in JAMA ! Chidamide DEB Study Reshapes the First-Line Treatment Landscape for DE-DLBCL

Full text

2026.04.18

AACR 2026 | Dual Breakthroughs in Novel Target ADCs and Small Molecules: Four Original Oncology Pipeline Studies from Chipscreen and Chipscreen Newway Biosciences Accepted for Presentation

AACR 2026 | Dual Breakthroughs in Novel Target ADCs and Small Molecules: Four Original Oncology Pipeline Studies from Chipscreen and Chipscreen Newway Biosciences Accepted for Presentation

Full text

2026.03.16

First-in-Class Combination Therapy: Clinical Trial Application for Chiglitazar Sodium/Metformin Extended-Release Tablets for Type 2 Diabetes Approved

First-in-Class Combination Therapy: Clinical Trial Application for Chiglitazar Sodium/Metformin Extended-Release Tablets for Type 2 Diabetes Approved

Full text

2026.03.16

Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors

Chipscreen Biosciences Receives NMPA Approval for IND of Novel PRMT5 Inhibitor CS08399 for MTAP-Deficient Tumors

Full text

2025.12.07

Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug

Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug

Full text

2025.12.05

Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award

Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award

Full text

2025.11.19

Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery

Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery

Full text

2025.11.15

Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF

Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF

Full text

2025.11.03

ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%

ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%

Full text

2025.10.15

ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session

ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session

Full text

2025.09.25

Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards

Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards

Full text

2025.08.18

Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development

Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development

Full text

2025.08.07

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

Full text

2025.07.31

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

Full text